Mycobacterium Avium Complex Clinical Trial
Official title:
A Randomized Controlled Trial on Hypertonic Saline Inhalation in Patients With Nodular-bronchiectatic Mycobacterium Avium Complex Pulmonary Disease
The SALINE trial will investigate the effect of Hypertonic Saline inhalation plus best supportive care on burden of symptoms, clearance of mycobacteria and functional capacities in participants with Mycobacterium avium complex lung disease and compare the effect to treatment with best supportive care alone.
The treatment of Mycobacterium avium complex (MAC) lung disease consists of best supportive care, often accompanied by long-lasting multi-drug antibiotic regimens. Two major radiologic patterns exist: nodular-bronchiectatic and fibrocavitary disease, characterized by slow and rapid progression of disease, respectively. SALINE is an open-label, randomized, two-arm controlled study that investigates the effect of Hypertonic Saline inhalation (HSi) plus best supportive care versus best supportive care alone for 12 weeks in participants with nodular-bronchiectatic MAC lung disease. The investigators hypothesize that HSi added to best supportive care will improve health-related quality of life and reduce mycobacterial load more than best supportive care alone Participants will be randomized 1:1 to a study arm. Best supportive care comprises of management of a predisposing (lung) condition, guidance in smoking cessation, respiratory physiotherapy (e.g. airway clearance) and nutritional guidance. HSi will be administered two times daily. Antibacterial therapy against other bacterial infections and inhaled corticosteroids are allowed during the study period. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT01719042 -
Improving Tolerance of Treatment of Pulmonary MAC Infections
|
Phase 2 | |
| Completed |
NCT00600769 -
Clarithromycin for the Treatment of Infections Caused by Nontuberculous Mycobacteria (NTM)
|
Phase 4 | |
| Recruiting |
NCT03236987 -
CLArithromycin Versus AZIthromycin in the Treatment of Mycobacterium Avium Complex (MAC) Lung Infections
|
Phase 3 | |
| Recruiting |
NCT04287049 -
A Study of Standard Drugs for Mycobacterium Avium Complex
|
Phase 2 | |
| Recruiting |
NCT03672630 -
Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease
|
Phase 2/Phase 3 | |
| Completed |
NCT04685720 -
A Pilot Study to Assess the Effect of Intermittent iNO on the Treatment of NTM Lung Infection in CF and Non-CF Patients
|
N/A | |
| Terminated |
NCT04553406 -
Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease
|
Phase 2 | |
| Completed |
NCT00598962 -
Use of Azithromycin and Rifabutin Administered 3 Times Weekly for the Treatment of M. Avium Complex (MAC) Lung Disease
|
Phase 4 | |
| Recruiting |
NCT05824988 -
Drug Exposure and Minimum Inhibitory Concentration in the Treatment of MAC Lung Disease
|
||
| Recruiting |
NCT02968212 -
Clofazimine in the Treatment of Pulmonary Mycobacterium Avium Complex (MAC)
|
Phase 2 |